title: Prognostic factors in surgically managed gastrointestinal stromal tumours.
abstract: OBJECTIVE
  To determine prognostic factors associated with survival in patients with surgically managed gastrointestinal stromal tumours (GISTs).
  
  
  METHODS
  This retrospective study included 374 patients with pathologically confirmed GISTs. Medical records were reviewed and prognostic  factors associated with adverse outcomes were determined.
  
  
  RESULTS
  A total of 337 patients underwent complete resection with curative intent; 37 underwent incomplete resection. Overall mean survival time was 127.3 months; 5-year survival rate was 70.4%. Multivariate analyses determined that  tumour size, risk status (of recurrence or metastasis) and surgical procedure were significant predictive factors for survival. There was a significant difference in the 5-year survival rate between patients who received adjuvant imatinib compared with those who did not (75.1% versus 13.8%).
  
  
  CONCLUSIONS
  Patients with GISTs managed by surgical resection combined with targeted chemotherapy had a good prognosis. Clinical factors predictive of survival included tumour size, risk status and surgical procedure.
authors.affiliation: Department of Colorectal Surgery, Cancer Centre, Sun Yat-sen University/State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China.
authors.forename: X-J
authors.initials: XJ
authors.lastname: Wu
authors.forename: R-X
authors.initials: RX
authors.lastname: Zhang
authors.forename: G
authors.initials: G
authors.lastname: Chen
authors.forename: Y-J
authors.initials: YJ
authors.lastname: Fang
authors.forename: P-R
authors.initials: PR
authors.lastname: Ding
authors.forename: L-R
authors.initials: LR
authors.lastname: Li
authors.forename: Z-H
authors.initials: ZH
authors.lastname: Lu
authors.forename: L-H
authors.initials: LH
authors.lastname: Kong
authors.forename: Z-Z
authors.initials: ZZ
authors.lastname: Pan
authors.forename: D-S
authors.initials: DS
authors.lastname: Wan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D046152:Gastrointestinal Stromal Tumors / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D006801:Humans; D000068877:Imatinib Mesylate; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate